Many in the Type 1 diabetes community wish for two things: lower insulin prices and non-injectable insulin. Now, there’s evidence that the former may have killed off the latter. According to a Fierce Biotech report, Novo Nordisk announced in an October 31st earnings call that it is halting research and development efforts aimed at creating an oral form of insulin.

Read more